| Literature DB >> 35429245 |
Akinao Kaneta1, Shotaro Nakajima2, Hirokazu Okayama1, Takuro Matsumoto1, Katsuharu Saito1, Tomohiro Kikuchi1, Eisei Endo1, Misato Ito1, Kosaku Mimura1,3, Yasuyuki Kanke1, Motonobu Saito1, Zenichiro Saze1, Shotaro Fujita1, Wataru Sakamoto1, Hisashi Onozawa1, Tomoyuki Momma1, Shinji Ohki1, Koji Kono1.
Abstract
Deficient mismatch repair (dMMR)/microsatellite instability (MSI) colorectal cancer (CRC) has high immunogenicity and better prognosis compared with proficient MMR (pMMR)/microsatellite stable (MSS) CRC. Although the activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway has been considered to contribute to the high number of CD8+ TILs, its role in dMMR/MSI CRC is largely unknown. In this study, to examine the role of the cGAS-STING pathway on the recruitment of CD8+ TILs in dMMR/MSI CRC, we used public datasets and clinical tissue samples in our cohorts to evaluate the expression of cGAS, STING, and CD8+ TILs in pMMR/MSS and dMMR/MSI CRCs. According to the analysis of public datasets, the expression of cGAS-STING, CD8 effector gene signature, and CXCL10-CCL5, chemoattractants for CD8+ TILs which regulated by the cGAS-STING pathway, was significantly upregulated in dMMR/MSI CRC, and the expression of cGAS-STING was significantly associated with the expression of CD8 effector gene signature. Immunohistochemistry staining of the clinical tissue samples (n = 283) revealed that cGAS-STING was highly expressed in tumor cells of dMMR CRC, and higher expression of cGAS-STING in tumor cells was significantly associated with the increased number of CD8+ TILs. Moreover, we demonstrated that the downregulation of MMR gene in human CRC cell lines enhanced the activation of the cGAS-STING pathway. Taken together, for the first time, we found that dMMR/MSI CRC has maintained a high level of cGAS-STING expression in tumor cells, which might contribute to abundant CD8+ TILs and immune-active TME.Entities:
Keywords: CD8+ TIL; Colorectal cancer; cGAS-STING; dMMR/MSI; pMMR/MSS
Mesh:
Substances:
Year: 2022 PMID: 35429245 DOI: 10.1007/s00262-022-03200-w
Source DB: PubMed Journal: Cancer Immunol Immunother ISSN: 0340-7004 Impact factor: 6.630